Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Survival and clinical response to bortezomib, thalidomide, and dexamethasone in patients with multiple myeloma at a peruvian tertiary care center: A real-world retrospective observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

BAB. Alegre

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows improved progression-free survival in multiple myeloma patients with autologous stem cell transplantation, suggesting effective treatment strategies in resource-lim

Key Points

  • Median progression-free survival was 46 months in multiple myeloma patients receiving VTD treatment.
  • Autologous stem cell transplantation significantly reduced the risk of progression by 80% and death by 82%.
  • This retrospective observational study reviewed outcomes for patients treated with the VTD regimen in Peru.
  • VTD is effective in resource-limited settings, reinforcing the importance of access to comprehensive cancer care.

Cite This Study

B. Alegre (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1dahttps://doi.org/10.1182/blood-2025-7518
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025
  2. 2Assessment of treatment outcomes in multiple myeloma according to prognostic factors and therapeutic approach2025
  3. 3Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy2025
  4. 4Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy2025
  5. 5Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study2025